Health
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant – The BMJ
The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection…
The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection against the newer variants B.1.1.7 (85.6%) and B.1.351 (60%), preliminary data from clinical trials show.
Interim results have been released from a phase III trial carried out in the UK with more than 15 000 participants aged between 18 and 84, including 27% over the age of 65. The trial tested two doses of the vaccine administered three…
-
General17 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Business24 hours agoInvested $10,000 in Westpac shares 2 years ago? Guess how much you’ve already banked!
-
Noosa News16 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years
-
General20 hours agoBack-to-back rate cuts tipped when Reserve Bank meets